"This strategic partnership is another example of our commitment to address unmet needs in the animal health market" - Stephen Martin, Boehringer Ingelheim Animal Health.

Boehringer Ingelheim and MabGenesis will combine their expertise to develop new products.   

Boehringer Ingelheim and biopharmaceutical firm MabGenesis are joining forces to discover new canine monoclonal antibodies for potential therapeutic treatments. 

The partnership will see MabGenesis apply its unique technology platform to discover first class antibodies against targets of interest selected by Boehringer Ingelheim. 

While the terms of the agreement have not been disclosed, Boehringer will have the right to develop and commercialise the resulting products for the veterinary market. 

Katsuhiro Shinjo, chief executive officer of MabGenesis, said: “We are excited to partner with global animal health leader Boehringer Ingelheim as we feel we bring complementary expertise to this collaboration. 

“The combination of our innovative discovery platform, MOURA Library and IMPACT, and Boehringer Ingelheim’s capability and industry leadership will surely lead to the discovery of innovative canine therapeutic antibodies bringing benefits to animal health.”

Boehringer Ingelheim said that strengthening partnership to accelerate innovation is key in its research and development strategy. 

Stephen Martin, head of research at Boehringer Ingelheim Animal Health, said: “We believe that collaboration and shared innovation can lead to groundbreaking solutions to better predict, prevent, detect and treat diseases.

"This strategic partnership is another example of our commitment to address unmet needs in the animal health market with the aim to improve the lives of animals and humans.”